-
Product Insights
United Kingdom (UK) Private Motor Insurance Distribution Dynamics and Future Market, 2023 Update
UK Private Motor Insurance Market Overview The UK private motor insurance market research report offers insights into the motor insurance scenario within the private insurance market and how it is influenced by upcoming regulatory changes and volatility in the economy. It also ascertains how newcomers and insurtechs are disrupting and driving innovation in the country’s insurance industry. The report enables clients to identify the effects of emerging technologies such as artificial intelligence and autonomous vehicles on the UK private motor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Refractory Acute Myeloid Leukemia Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Motixafortide Acetate in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Motixafortide Acetate in Sickle Cell Disease Drug Details: Motixafortide is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trabedersen in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trabedersen in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trabedersen in Pancreatic Cancer Drug Details: Trabedersen (OT-101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trabedersen in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trabedersen in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trabedersen in Solid Tumor Drug Details: Trabedersen (OT-101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritumumab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Non-Small Cell Lung Cancer Drug Details: Pritumumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Anaplastic Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritumumab in Anaplastic Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Anaplastic Astrocytoma Drug Details: Pritumumab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Chordoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritumumab in Chordoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Chordoma Drug Details: Pritumumab is under development for the treatment of...